var data={"title":"Calculator: International Prognostic Index for non-Hodgkin lymphoma in adults","body":"<div id=\"topicContentCalculator\" class=\"utdArticleSection\"><div id=\"topicText\">\n<div id=\"mc3k\">\n\n\n\n\n<form name=\"IPINHL_form\" id=\"IPINHL_form\" action=\"\" onsubmit=\"return false;\" onreset=\"rrclr(); \">\n<table width=\"100%\" cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">\n<tr><td bgcolor=\"#eeeeee\" width=\"1%\"><br /></td>\n<td bgcolor=\"#eeeeee\" align=\"left\">\n<span class=\"medCalcFontTitleBox\">\n\n \nCalculator: International Prognostic Index for non-Hodgkin lymphoma in adults\n</span></td></tr></table><br />&nbsp;<br />\n<div id=\"calc_main\">\n<div id=\"calc_input\">\n<center>\n<table cellpadding=\"3\" cellspacing=\"0\" summary=\"EBMcalc Table\">\n<tr><td width=\"20\"><br /></td>\n<td align=\"right\"><input type=\"checkbox\" name=\"cc1\" onclick=\"IPINHL_fx();\" /></td>\n<td align=\"left\"><span class=\"medCalcFontCCTab\">Age &gt;60 years old (1 point)</span></td></tr>\n<tr><td width=\"20\"><br /></td>\n<td align=\"right\"><input type=\"checkbox\" name=\"cc2\" onclick=\"IPINHL_fx();\" /></td>\n<td align=\"left\"><span class=\"medCalcFontCCTab\">Serum lactate dehydrogenase concentration above normal (1 point)</span></td></tr>\n<tr><td width=\"20\"><br /></td>\n<td align=\"right\"><input type=\"checkbox\" name=\"cc3\" onclick=\"IPINHL_fx();\" /></td>\n<td align=\"left\"><span class=\"medCalcFontCCTab\">Ann Arbor stage III or IV (1 point)</span></td></tr>\n<tr><td width=\"20\"><br /></td>\n<td align=\"right\"><input type=\"checkbox\" name=\"cc4\" onclick=\"IPINHL_fx();\" /></td>\n<td align=\"left\"><span class=\"medCalcFontCCTab\">More than one extranodal disease site (1 point)</span></td></tr>\n<tr><td colspan=\"3\" align=\"left\"><span class=\"medCalcFontCCTabBold\">ECOG performance scale </span></td></tr>\n<tr><td width=\"20\"><br /></td>\n<td align=\"right\"><input type=\"radio\" name=\"cc5\" onclick=\"IPINHL_fx();\" /></td>\n<td align=\"left\"><span class=\"medCalcFontCCTab\"> Performance status 0: Fully active; no performance restrictions (0 points)</span></td></tr>\n<tr><td width=\"20\"><br /></td>\n<td align=\"right\"><input type=\"radio\" name=\"cc5\" onclick=\"IPINHL_fx();\" /></td>\n<td align=\"left\"><span class=\"medCalcFontCCTab\"> Performance status 1: Strenuous physical activity restricted; fully ambulatory and able to carry out light work (0 points)</span></td></tr>\n<tr><td width=\"20\"><br /></td>\n<td align=\"right\"><input type=\"radio\" name=\"cc5\" onclick=\"IPINHL_fx();\" /></td>\n<td align=\"left\"><span class=\"medCalcFontCCTab\"> Performance status 2: Capable of all self-care but unable to carry out any work activities. Up and about &gt;50 percent of waking hours (1 point)</span></td></tr>\n<tr><td width=\"20\"><br /></td>\n<td align=\"right\"><input type=\"radio\" name=\"cc5\" onclick=\"IPINHL_fx();\" /></td>\n<td align=\"left\"><span class=\"medCalcFontCCTab\"> Performance status 3: Capable of only limited self-care; confined to bed or chair &gt;50 percent of waking hours (1 point)</span></td></tr>\n<tr><td width=\"20\"><br /></td>\n<td align=\"right\"><input type=\"radio\" name=\"cc5\" onclick=\"IPINHL_fx();\" /></td>\n<td align=\"left\"><span class=\"medCalcFontCCTab\"> Performance status 4: Completely disabled; cannot carry out any self-care; totally confined to bed or chair (1 point)</span></td></tr>\n\n</table>\n</center>\n</div>\n<br />&nbsp;<br />\n<div id=\"calc_result\">\n<span class=\"medCalcFontCCTabBold\">\nTotal criteria point count:\n</span>\n<input type=\"text\" size=\"6\" name=\"cctotal\" onfocus=\"blur();\" /><br />&nbsp;<br />\n<center><input type=\"reset\" name=\"reset\" value=\"Reset form\" />    </center>\n<br />&nbsp;<br />\n<table width=\"70%\" cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">\n<tr><td bgcolor=\"#eeeeee\" width=\"1%\"><br /></td>\n<td bgcolor=\"#eeeeee\" align=\"left\">    \n<span class=\"medCalcFontTitleBox\">\n\n When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5 year overall survival (OS) and complete response (CR) rates were as follows:\n</span></td></tr></table><br />&nbsp;<br />\n<center>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">\n<tr id=\"rr1_1\"><td align=\"right\" style=\"border-right: 0px;\" nowrap=\"nowrap\"><span class=\"medCalcFontOneBold\">0 to 1 point:</span></td>\n<td align=\"left\" style=\"border-left: 0px;\"><span class=\"medCalcFontOne\">Low risk with 73% 5 year OS and 87% CR</span></td></tr>\n<tr id=\"rr1_2\"><td align=\"right\" style=\"border-right: 0px;\" nowrap=\"nowrap\"><span class=\"medCalcFontOneBold\">2 points:</span></td>\n<td align=\"left\" style=\"border-left: 0px;\"><span class=\"medCalcFontOne\"> Low-intermediate risk with 51% 5 year OS and 67% CR</span></td></tr>\n<tr id=\"rr1_3\"><td align=\"right\" style=\"border-right: 0px;\" nowrap=\"nowrap\"><span class=\"medCalcFontOneBold\">3 points:</span></td>\n<td align=\"left\" style=\"border-left: 0px;\"><span class=\"medCalcFontOne\"> High-intermediate risk with 43% 5 year OS and 55% CR</span></td></tr>\n<tr id=\"rr1_4\"><td align=\"right\" style=\"border-right: 0px;\" nowrap=\"nowrap\"><span class=\"medCalcFontOneBold\">4 to 5 points:</span></td>\n<td align=\"left\" style=\"border-left: 0px;\"><span class=\"medCalcFontOne\"> High risk with 26% 5 year OS and 44% CR</span></td></tr>\n\n</table>\n</center>\n<br />&nbsp;<br />\n<br />&nbsp;<br />\n<table width=\"70%\" cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">\n<tr><td bgcolor=\"#eeeeee\" width=\"1%\"><br /></td>\n<td bgcolor=\"#eeeeee\" align=\"left\">    \n<span class=\"medCalcFontTitleBox\">\n\n When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3 year event-free survival (EFS),  progression free survival (PFS) and overall survival (OS) were as follows:\n</span></td></tr></table><br />&nbsp;<br />\n<center>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">\n<tr id=\"rr2_5\"><td align=\"right\" style=\"border-right: 0px;\" nowrap=\"nowrap\"><span class=\"medCalcFontOneBold\">0 to 1 point:</span></td>\n<td align=\"left\" style=\"border-left: 0px;\"><span class=\"medCalcFontOne\"> EFS 81%, PFS 87% and OS 91%</span></td></tr>\n<tr id=\"rr2_6\"><td align=\"right\" style=\"border-right: 0px;\" nowrap=\"nowrap\"><span class=\"medCalcFontOneBold\">2 points:</span></td>\n<td align=\"left\" style=\"border-left: 0px;\"><span class=\"medCalcFontOne\"> EFS 69%, PFS 75% and OS 81%</span></td></tr>\n<tr id=\"rr2_7\"><td align=\"right\" style=\"border-right: 0px;\" nowrap=\"nowrap\"><span class=\"medCalcFontOneBold\">3 points:</span></td>\n<td align=\"left\" style=\"border-left: 0px;\"><span class=\"medCalcFontOne\"> EFS 53%, PFS 59% and OS 65%</span></td></tr>\n<tr id=\"rr2_8\"><td align=\"right\" style=\"border-right: 0px;\" nowrap=\"nowrap\"><span class=\"medCalcFontOneBold\">4 to 5 points:</span></td>\n<td align=\"left\" style=\"border-left: 0px;\"><span class=\"medCalcFontOne\"> EFS 50%, PFS 50% and OS 59%</span></td></tr>\n\n</table>\n</center>\n<br />&nbsp;<br />\n\n</div>\n</div>\n\n<div id=\"calc_notes\">\n<span class=\"medCalcFontOneBold\">Notes</span>\n<ul class=\"medCalcFontOne\">\n<li><b>ECOG</b>: Eastern Cooperative Oncology Group</li>\n<li><b>NHL</b>: Non-Hodgkin lymphoma</li>\n\n</ul>\n</div>\n\n<br />&nbsp;<br />\n\n<div id=\"calc_refs\">\n<span class=\"medCalcFontRef\"><b>References</b></span>\n<ol>\n<li><span class=\"medCalcFontRef\">The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive  non-Hodgkin's lymphoma. <i>N Engl J Med</i>. 1993; 329:987.</span></li>\n<li><span class=\"medCalcFontRef\">Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid  predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. <i> J Clin Oncol</i>. 2010; 28:2373. Epub 2010 Apr 12. Erratum in: J Clin Oncol 2011; 29:779.</span></li>\n<li><span class=\"medCalcFontRef\">Oken MM, Creech RH, Tormey DC, et al, Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair.  Toxicity and response criteria of the Eastern Cooperative Oncology Group. <i> Am J Clin Oncol</i>. 1982; 5:649.</span></li>\n\n</ol>\n</div>\n\n \n</form>\n\n\n\n\n</div>\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"printDisclaimer\">\r\n\t<b>Only digits 0 to 9 and a single decimal point (&quot;.&quot;) are acceptable as numeric inputs. Attempted input of other characters into a numeric field may lead to an incorrect result.</b>\r\n\t<p>\r\n\tInformation on this page may not appear correctly if printed. </p>\r\n</div>\r\n<div id=\"disclaimerCalculator\">\r\n\t<div class=\"medCalcFontTwo\">\r\n\t\t<p class=\"header\">Legal Notices and Disclaimer</p>\r\n\t\t<p>\r\n\t\t\tAll information contained in and produced by the EBMcalc system is provided\r\n\t\t\tfor educational purposes only. This information should not be used for the diagnosis or treatment\r\n\t\t\tof any health problem or disease. \r\n\t\t\t<b>THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.</b>\r\n\t\t\t<a href=\"https://www.uptodate.com/legal/ebmcalc-disclaimer\" class=\"medCalcDisclaimerLink\">Click here for full notice and disclaimer.</a>\r\n\t\t</p>\r\n\t\t<p class=\"copy\">EBMcalc is Copyright &copy; 1998-2018 Foundation Internet Services, LLC</p>\r\n\t</div>\r\n</div><div id=\"topicVersionRevision\">Topic 87307 Version 3.0</div></div>","outline":null,"javascript":"\n/* <![CDATA[ */\n\n\n\nvar calctxt = '';\nvar xmltxt = '';\nvar xmlresult = '';\nvar htmtxt = '';\nvar postNow = false;\n\n\nfunction IPINHL_fx() {\nwith(document.IPINHL_form){\n\nScore = 0.0;\ndoCalc = true;\n\nif (cc1.checked){\nScore = Score + 1;\n}\nif (cc2.checked){\nScore = Score + 1;\n}\nif (cc3.checked){\nScore = Score + 1;\n}\nif (cc4.checked){\nScore = Score + 1;\n}\nif (cc5[0].checked){\nScore = Score + 0; \n}\nif (cc5[1].checked){\nScore = Score + 0; \n}\nif (cc5[2].checked){\nScore = Score + 1; \n}\nif (cc5[3].checked){\nScore = Score + 1; \n}\nif (cc5[4].checked){\nScore = Score + 1; \n}\nif (doCalc){\ncctotal.value = Score;\nif (cctotal.value == 'NaN') cctotal.value = '';\n}\nelse{\nScore = null;\ncctotal.value = '';\nif (typeof rrclr == 'function') { rrclr(); };\ndocument.IPINHL_form.cctotal.value = '';\n}\n\nif (doCalc){\nrrclr();\nif (( Score >= 0) && ( Score <= 1)){ document.getElementById('rr1_1').bgColor = '#cccccc';\n}\nif (( Score >= 2) && ( Score <= 2)){ document.getElementById('rr1_2').bgColor = '#cccccc';\n}\nif (( Score >= 3) && ( Score <= 3)){ document.getElementById('rr1_3').bgColor = '#cccccc';\n}\nif (( Score >= 4) && ( Score <= 5)){ document.getElementById('rr1_4').bgColor = '#cccccc';\n}\nif ((Score >= 0) && (Score <= 1)){ document.getElementById('rr2_5').bgColor = '#cccccc';\n}\nif ((Score >= 2) && (Score <= 2)){ document.getElementById('rr2_6').bgColor = '#cccccc';\n}\nif ((Score >= 3) && (Score <= 3)){ document.getElementById('rr2_7').bgColor = '#cccccc';\n}\nif ((Score >= 4) && (Score <= 5)){ document.getElementById('rr2_8').bgColor = '#cccccc';\n}\n\n\n}\n}\n}\n\n\n\n\nfunction rrclr(){\ndocument.getElementById('rr1_1').bgColor = '';\ndocument.getElementById('rr1_2').bgColor = '';\ndocument.getElementById('rr1_3').bgColor = '';\ndocument.getElementById('rr1_4').bgColor = '';\ndocument.getElementById('rr2_5').bgColor = '';\ndocument.getElementById('rr2_6').bgColor = '';\ndocument.getElementById('rr2_7').bgColor = '';\ndocument.getElementById('rr2_8').bgColor = '';\n}\n\n\n\n\n/* ]]> */\n\n/* <![CDATA[ */\n\n\n\nIPINHL_fx();\n\n/* ]]> */\n"}